Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070244 | 0.83 | ALDH1A1 (0.41) | LTA4HMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL6475571 | 0.81 | IDO1 (0.46) | LTA4HMAPTRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL3489533 | 0.75 | MAPT (0.58) | LTA4HMAPK14MAPTL3MBTL1RAB9A | |
| SCHEMBL4074725 | 0.74 | IDO1 (0.53) | LTA4HMAPK14MAPTL3MBTL1RAB9A | |
| SCHEMBL4971255 | 0.73 | MAOB (0.43) | LTA4HMAPK14MAPTL3MBTL1RAB9A | |
| SCHEMBL25231432 | 0.73 | HTR2A (0.42) | SMN1; SMN2 | |
| SCHEMBL30539480 | 0.73 | HTR2A (0.42) | SMN1; SMN2 | |
| SCHEMBL27640492 | 0.73 | CALM1 (0.42) | LTA4HMAPTSMN1; SMN2MAOBGAA | |
| SCHEMBL34472968 | 0.72 | KDM1A (0.50) | LTA4HMAPK14MAPTL3MBTL1RAB9A | |
| SCHEMBL11828242 | 0.72 | MAPT (0.64) | LTA4HMAPK14MAPTL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | US | disclosed |
| EP-1341768-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046168-A1 | THERAPEUTIC BENZIMIDAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004713-A1 | Therapeutic benimidazole compounds | ESR2, ESRRA, ESRRB | LTA4H 3366/4885MAPK14 2159/4885MAPT 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.